These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36601958)

  • 1. Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study.
    Omran M; Johansson H; Lundgren C; Silander G; Stenmark-Askmalm M; Loman N; Baan A; Adra J; Kuchinskaya E; Blomqvist L; Tham E; Bajalica-Lagercrantz S; Brandberg Y;
    Cancer; 2023 Mar; 129(6):946-955. PubMed ID: 36601958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic
    Bancroft EK; Saya S; Brown E; Thomas S; Taylor N; Rothwell J; Pope J; Chamberlain A; Page E; Benafif S; Hanson H; Dias A; Mikropoulos C; Izatt L; Side L; Walker L; Donaldson A; Cook JA; Barwell J; Wiles V; Limb L; Eccles DM; Leach MO; Shanley S; Gilbert FJ; Gallagher D; Rajashanker B; Whitehouse RW; Koh DM; Sohaib SA; Evans DG; Eeles RA; Walker LG
    J Med Genet; 2020 Apr; 57(4):226-236. PubMed ID: 31719169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
    Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC
    Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-Body MRI Surveillance-Baseline Findings in the Swedish Multicentre Hereditary
    Omran M; Tham E; Brandberg Y; Ahlström H; Lundgren C; Paulsson-Karlsson Y; Kuchinskaya E; Silander G; Rosén A; Persson F; Leonhardt H; Stenmark-Askmalm M; Berg J; van Westen D; Bajalica-Lagercrantz S; Blomqvist L;
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey.
    Rippinger N; Fischer C; Haun MW; Rhiem K; Grill S; Kiechle M; Cremer FW; Kast K; Nguyen HP; Ditsch N; Kratz CP; Vogel J; Speiser D; Hettmer S; Glimm H; Fröhling S; Jäger D; Seitz S; Hahne A; Maatouk I; Sutter C; Schmutzler RK; Dikow N; Schott S
    Cancer; 2020 Sep; 126(17):4032-4041. PubMed ID: 32557628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
    Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
    Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
    de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA
    Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?
    McBride KA; Ballinger ML; Schlub TE; Young MA; Tattersall MHN; Kirk J; Eeles R; Killick E; Walker LG; Shanley S; Thomas DM; Mitchell G
    Fam Cancer; 2017 Jul; 16(3):423-432. PubMed ID: 28124295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance recommendations for patients with germline TP53 mutations.
    Ballinger ML; Mitchell G; Thomas DM
    Curr Opin Oncol; 2015 Jul; 27(4):332-7. PubMed ID: 26049273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.
    Villani A; Tabori U; Schiffman J; Shlien A; Beyene J; Druker H; Novokmet A; Finlay J; Malkin D
    Lancet Oncol; 2011 Jun; 12(6):559-67. PubMed ID: 21601526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
    Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
    Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parent decision-making around the genetic testing of children for germline TP53 mutations.
    Alderfer MA; Zelley K; Lindell RB; Novokmet A; Mai PL; Garber JE; Nathan D; Scollon S; Chun NM; Patenaude AF; Ford JM; Plon SE; Schiffman JD; Diller LR; Savage SA; Malkin D; Ford CA; Nichols KE
    Cancer; 2015 Jan; 121(2):286-93. PubMed ID: 25223899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
    Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
    JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.
    Ballinger ML; Best A; Mai PL; Khincha PP; Loud JT; Peters JA; Achatz MI; Chojniak R; Balieiro da Costa A; Santiago KM; Garber J; O'Neill AF; Eeles RA; Evans DG; Bleiker E; Sonke GS; Ruijs M; Loo C; Schiffman J; Naumer A; Kohlmann W; Strong LC; Bojadzieva J; Malkin D; Rednam SP; Stoffel EM; Koeppe E; Weitzel JN; Slavin TP; Nehoray B; Robson M; Walsh M; Manelli L; Villani A; Thomas DM; Savage SA
    JAMA Oncol; 2017 Dec; 3(12):1634-1639. PubMed ID: 28772291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
    Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
    J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes.
    Frebourg T; Bajalica Lagercrantz S; Oliveira C; Magenheim R; Evans DG;
    Eur J Hum Genet; 2020 Oct; 28(10):1379-1386. PubMed ID: 32457520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls.
    Saya S; Killick E; Thomas S; Taylor N; Bancroft EK; Rothwell J; Benafif S; Dias A; Mikropoulos C; Pope J; Chamberlain A; Gunapala R; ; Izatt L; Side L; Walker L; Tomkins S; Cook J; Barwell J; Wiles V; Limb L; Eccles D; Leach MO; Shanley S; Gilbert FJ; Hanson H; Gallagher D; Rajashanker B; Whitehouse RW; Koh DM; Sohaib SA; Evans DG; Eeles RA
    Fam Cancer; 2017 Jul; 16(3):433-440. PubMed ID: 28091804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.
    Dixon-Zegeye M; Shaw R; Collins L; Perez-Smith K; Ooms A; Qiao M; Pantziarka P; Izatt L; Tischkowitz M; Harrison RE; George A; Woodward ER; Lord S; Hawkes L; Evans DG; Franklin J; Hanson H; Blagden SP
    Trials; 2024 Feb; 25(1):103. PubMed ID: 38308321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
    Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
    JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort.
    Mai PL; Khincha PP; Loud JT; DeCastro RM; Bremer RC; Peters JA; Liu CY; Bluemke DA; Malayeri AA; Savage SA
    JAMA Oncol; 2017 Dec; 3(12):1640-1645. PubMed ID: 28772286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.